A detailed history of Pallas Capital Advisors LLC transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Pallas Capital Advisors LLC holds 15,934 shares of NUVB stock, worth $42,703. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,934
Previous 13,357 19.29%
Holding current value
$42,703
Previous $39,000 7.69%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$2.3 - $3.83 $5,927 - $9,869
2,577 Added 19.29%
15,934 $36,000
Q2 2024

Jul 19, 2024

BUY
$2.58 - $3.69 $4,613 - $6,597
1,788 Added 15.46%
13,357 $39,000
Q1 2024

Apr 15, 2024

BUY
$1.46 - $3.97 $2,290 - $6,228
1,569 Added 15.69%
11,569 $42,000
Q4 2023

Jan 22, 2024

SELL
$0.96 - $1.53 $272 - $434
-284 Reduced 2.76%
10,000 $15,000
Q2 2023

Jul 26, 2023

BUY
$1.56 - $1.84 $443 - $522
284 Added 2.84%
10,284 $18,000
Q1 2022

Apr 20, 2022

BUY
$4.6 - $8.83 $46,000 - $88,300
10,000 New
10,000 $55,000

Others Institutions Holding NUVB

About Nuvation Bio Inc.


  • Ticker NUVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 217,244,000
  • Market Cap $582M
  • Description
  • Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...
More about NUVB
Track This Portfolio

Track Pallas Capital Advisors LLC Portfolio

Follow Pallas Capital Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pallas Capital Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pallas Capital Advisors LLC with notifications on news.